[
  {
    "ts": null,
    "headline": "Amazon and Apple earnings coverage, Eli Lilly: What to Watch",
    "summary": "Market Domination Overtime hosts Julie Hyman and Josh Lipton preview several of the biggest stories and reports due out tomorrow, Thursday, May 1, including Apple (AAPL) and Amazon's (AMZN) respective quarterly earnings results alongside Eli Lilly (LLY), Mastercard (MA), McDonald's (MCD), and CVS Health (CVS). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
    "url": "https://finnhub.io/api/news?id=df2b9307b9d5d0e211a07c09f4c5130fc294ec295df18da85e79cbabe9ceb01d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746054052,
      "headline": "Amazon and Apple earnings coverage, Eli Lilly: What to Watch",
      "id": 134165686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Market Domination Overtime hosts Julie Hyman and Josh Lipton preview several of the biggest stories and reports due out tomorrow, Thursday, May 1, including Apple (AAPL) and Amazon's (AMZN) respective quarterly earnings results alongside Eli Lilly (LLY), Mastercard (MA), McDonald's (MCD), and CVS Health (CVS). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
      "url": "https://finnhub.io/api/news?id=df2b9307b9d5d0e211a07c09f4c5130fc294ec295df18da85e79cbabe9ceb01d"
    }
  },
  {
    "ts": null,
    "headline": "Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?",
    "summary": "Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.",
    "url": "https://finnhub.io/api/news?id=050d35b07ee9fba24431dd4b29cc4fc87883821e38242e62e934b4ea12ffd412",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746046080,
      "headline": "Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?",
      "id": 134165860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.",
      "url": "https://finnhub.io/api/news?id=050d35b07ee9fba24431dd4b29cc4fc87883821e38242e62e934b4ea12ffd412"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Earnings Report Will Bring a Focus on Tariffs, Not Profits",
    "summary": "Eli Lilly  virtually alone among its large-cap pharma peers, has been having an excellent year.  The stock is up by a double-digit percentage since the start of 2025, its market value is the largest in the healthcare sector, and it looks increasingly as though it has the weight-loss market firmly in hand.  All that means that when the company reports its first-quarter results on Thursday, investors’ focus will be less on the business than on rising external risks, particularly the sector-specific drug tariffs President Donald Trump has promised are on their way.",
    "url": "https://finnhub.io/api/news?id=f77f1d5e41d36ea12c6aadfe73553220e9ceadbf3ce9348a8a3bcb002bcdbf5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746045120,
      "headline": "Eli Lilly’s Earnings Report Will Bring a Focus on Tariffs, Not Profits",
      "id": 134165861,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly  virtually alone among its large-cap pharma peers, has been having an excellent year.  The stock is up by a double-digit percentage since the start of 2025, its market value is the largest in the healthcare sector, and it looks increasingly as though it has the weight-loss market firmly in hand.  All that means that when the company reports its first-quarter results on Thursday, investors’ focus will be less on the business than on rising external risks, particularly the sector-specific drug tariffs President Donald Trump has promised are on their way.",
      "url": "https://finnhub.io/api/news?id=f77f1d5e41d36ea12c6aadfe73553220e9ceadbf3ce9348a8a3bcb002bcdbf5d"
    }
  },
  {
    "ts": null,
    "headline": "Viagra and Mounjaro panic-buying could be behind a 200% export surge from Ireland to the U.S.",
    "summary": "U.S. multinational activity propelled the Irish economy to 3.2% growth in the first quarter, as Trump fears come into focus.",
    "url": "https://finnhub.io/api/news?id=0807be49c23cd806d62aa662f7a5de11a9e63fe8a3f70fb66f655b6df02bb922",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746012325,
      "headline": "Viagra and Mounjaro panic-buying could be behind a 200% export surge from Ireland to the U.S.",
      "id": 134165862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "U.S. multinational activity propelled the Irish economy to 3.2% growth in the first quarter, as Trump fears come into focus.",
      "url": "https://finnhub.io/api/news?id=0807be49c23cd806d62aa662f7a5de11a9e63fe8a3f70fb66f655b6df02bb922"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to lead oligonucleotide therapy development in new collaboration",
    "summary": "Eli Lilly and Company and Creyon Bio, Inc. have agreed to collaborate to advance novel RNA-targeted oligonucleotide therapies for both rare and common diseases.Under an exclusive license from Creyon,...",
    "url": "https://finnhub.io/api/news?id=717347b45d7476fb55f1041dddc9ba91a6a20ed6c7a0e8a2482818bc12af0def",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746009140,
      "headline": "Eli Lilly to lead oligonucleotide therapy development in new collaboration",
      "id": 134145394,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Company and Creyon Bio, Inc. have agreed to collaborate to advance novel RNA-targeted oligonucleotide therapies for both rare and common diseases.Under an exclusive license from Creyon,...",
      "url": "https://finnhub.io/api/news?id=717347b45d7476fb55f1041dddc9ba91a6a20ed6c7a0e8a2482818bc12af0def"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More",
    "summary": "Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price.  The company is also going after compounding pharmacies, which can result in more GLP-1 sales.  Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (NYSE: LLY).",
    "url": "https://finnhub.io/api/news?id=f7f228e1c01d92c36eb4973128a64f4d890a7f5f03179bcaf8f202e7de394c69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746006600,
      "headline": "Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More",
      "id": 134141565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price.  The company is also going after compounding pharmacies, which can result in more GLP-1 sales.  Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (NYSE: LLY).",
      "url": "https://finnhub.io/api/news?id=f7f228e1c01d92c36eb4973128a64f4d890a7f5f03179bcaf8f202e7de394c69"
    }
  },
  {
    "ts": null,
    "headline": "Why New Wegovy Deals Won’t Restore Novo Nordisk’s Obesity Lead",
    "summary": "The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only getting wider.",
    "url": "https://finnhub.io/api/news?id=4ae5045c2c1a610ea5472fe4d84191362d898375c33162dc1813109ad47e3a9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746005400,
      "headline": "Why New Wegovy Deals Won’t Restore Novo Nordisk’s Obesity Lead",
      "id": 134141566,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only getting wider.",
      "url": "https://finnhub.io/api/news?id=4ae5045c2c1a610ea5472fe4d84191362d898375c33162dc1813109ad47e3a9a"
    }
  },
  {
    "ts": null,
    "headline": "Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market",
    "summary": "Companies are developing myostatin inhibitors for GLP-1RA- related muscle loss, but some experts doubt their necessity.",
    "url": "https://finnhub.io/api/news?id=48943520b99f163430afc4760890631d61226b39d2b5b0a8fcac91df028237a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746000000,
      "headline": "Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market",
      "id": 134141568,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies are developing myostatin inhibitors for GLP-1RA- related muscle loss, but some experts doubt their necessity.",
      "url": "https://finnhub.io/api/news?id=48943520b99f163430afc4760890631d61226b39d2b5b0a8fcac91df028237a5"
    }
  },
  {
    "ts": null,
    "headline": "What To Expect From Eli Lilly’s (LLY) Q1 Earnings",
    "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow before market hours. Here’s what to look for.",
    "url": "https://finnhub.io/api/news?id=9bbe4b60833518635aa054352dacf096a16e55371e5b5594fae2eba5d9f1287d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745996881,
      "headline": "What To Expect From Eli Lilly’s (LLY) Q1 Earnings",
      "id": 134141569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow before market hours. Here’s what to look for.",
      "url": "https://finnhub.io/api/news?id=9bbe4b60833518635aa054352dacf096a16e55371e5b5594fae2eba5d9f1287d"
    }
  },
  {
    "ts": null,
    "headline": "Market Rally at Risk as Tariffs Damage Spreads. And 5 Other Things to Know Today.",
    "summary": "Market Rally at Risk as Tariffs Damage Spreads. And 5 Other Things to Know Today.",
    "url": "https://finnhub.io/api/news?id=3e744299a272d4cacf865ed898b568cd4b3ef94f2315e4f581ee0de25275ff9b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745996640,
      "headline": "Market Rally at Risk as Tariffs Damage Spreads. And 5 Other Things to Know Today.",
      "id": 134146024,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Market Rally at Risk as Tariffs Damage Spreads. And 5 Other Things to Know Today.",
      "url": "https://finnhub.io/api/news?id=3e744299a272d4cacf865ed898b568cd4b3ef94f2315e4f581ee0de25275ff9b"
    }
  }
]